Neural crete differenciation following constitutive activation of NRAS or BRAF proteins

Les mélanocytes sont des cellules productrices de mélanines, à l’origine de la teinte de la peau, des yeux et des cheveux. Elles dérivent d'une population multipotente appelée cellules de la crête neurale, qui génère entre autres également tout le système nerveux périphérique. Une prolifération accrue des précurseurs des mélanocytes durant le développement entraine chez l’homme l’apparition d’un nævus mélanocytaire congénital (NMC). Cette prolifération est due à une mutation somatique au sein d'un de ces précurseurs, dans des gènes de la voie de signalisation des MAP-Kinases, NRAS ou BRAF. Les plus grandes formes, couvrant des parties entières du corps, sont syndromiques. Ils peuvent associer des mélanocytoses, des malformations ou tumeurs cérébrales ou méningées, parfois épileptogènes, ainsi qu'un risque autour de 5% de dégénérer en mélanome, dans un des sites atteints. Durant ma thèse j’ai exploré des modèles murins où les protéines NRAS ou BRAF constitutivement actives sont exprimées très tôt au cours de l’embryogenèse, dans les cellules de la crête neurale. Les embryons mutants BrafV600E connaissent une létalité embryonnaire, probablement due à une superposition de défauts vasculaires et cérébraux. En revanche, les souris NrasG12D sont viables,présentent des mélanocytoses extracutanées dans des sites divers, ainsi qu’une hyperpigmentation cutanée, visible en postnatal. Cette hyperpigmentation est associée à une augmentation de la densité folliculaire, ainsi qu’à un dérèglement du cycle du follicule pileux. Des cultures de cellules de crête neurale murines, BrafV600E ou NrasG12D et contrôles, ont permis d’élucider sur le plan moléculaire les effets de telles mutations.Melanocytes are the vertebrate cells that produce melanin, conferring color on skin, hair and eyes. They arise from a multipotent embryonic cell population called the neural crest, which also gives rise to the peripheral nervous system of the body and many other cell types. Abnormal proliferation of melanocyte precursors before birth can lead to human congenital melanocytic nevus (CMN). CMN are caused by prenatal somatic mutations in the NRAS or BRAF genes of the MAP-Kinase pathway, in one of these precursors. The largest CMN, covering entire segments of the body or head, are syndromic. They are sometimes associated with epileptogenic brain or meningeal malformations, tumors or melanocytosis, and they present a risk of about 5% in all these sites of becoming pediatric malignant melanoma. During my thesis, I explored mouse models expressing constitutively activated NRAS or BRAF proteins in neural crest cell lineages, from very early in embryogenesis. BrafV600E mutant embryos are embryonic lethal at mid-gestation, probably due to coinciding vascular and brain defects. In contrast, NrasG12D mice are viable, present extracutaneous melanocytosis in various sites as well as postnatal hyperpigmentation of the skin. This is associated with increased hair follicle density, and a deregulated hair cycle. Cell culture of mutant or wildtype mouse neural crest cells of both genotypes has permitted the comparison and discovery of molecular differences introduced by these mutations

Deep phenotyping of MARS1 (interstitial lung and liver disease) and LARS1 (infantile liver failure syndrome 1) recessive multisystemic disease using Human Phenotype Ontology annotation: Overlap and differences. Case report and review of literature

International audienceIntroductionAminoacyl transfer RNA (tRNA) synthetases are associated with diseases when mutations occur in their encoding genes. Pulmonary alveolar proteinosis can be caused by mutation in the methionyl-tRNA synthetase (MARS) gene while mutations in the leucine-tRNA synthetase (LARS) gene lead to infantile liver failure syndrome type 1.We report the case of a patient with LARS1 pathogenics variants and two patients with MARS1 pathogenics variants. The aim of this study was to analyze the phenotypes of our three patients in detail and classify cases in the literature using Human Phenotype Ontology (HPO) terms.ResultsThe first patient has two previously undescribed heterozygous variants in LARS1 (c.1818dup and c.463A>G). The other two patients' MARS1 variants (c.1177G>A and c.1700C>T) have already been described in the literature.All three patients had anemia, hepatomegaly, feeding difficulties, failure to thrive and hypoalbuminemia.Including ours, 65 patients are described in total, for whom 117 phenotypic abnormalities have been described at least once, 41.9% of which both in patients with LARS1 and MARS1 mutations.ConclusionPatients with LARS1 and MARS1 mutations seem to share a common phenotype but further deep phenotyping studies are required to clarify the details of these complex pathologies

Comparison of generic and specific anxiety in patients treated with apalutamide plus active surveillance vs active surveillance alone for low and intermediate risk prostate cancer.

International audienc